Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.70 |
| ▸ | CA1 | P00915 | 8/20 | 0.70 |
| ▸ | CA2 | P00918 | 8/20 | 0.70 |
| ▸ | CA7 | P43166 | 8/20 | 0.70 |
| ▸ | CA9 | Q16790 | 8/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397366 | 0.98 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5267852 | 0.88 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10819681 | 0.83 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL29457577 | 0.83 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL38890 | 0.83 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13286843 | 0.81 | CA12 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28895697 | 0.80 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10787290 | 0.79 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7089488 | 0.79 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8021559 | 0.79 | CA12 (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58124728-A | — | — | None | — | — | JP | disclosed |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | disclosed |
| US-8053451-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | disclosed |
| EP-2371818-A1 | Hydroxybenzoate salts of metanicotine compounds | Targacept, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7989639-B2 | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | disclosed |
| WO-2011064237-A1 | CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| JP-S58124728-A | HYDROXYANTHRACENE DERIVATIVE | MATSUSHITA ELECTRIC IND CO LTD | 1983-07-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | CA12 4467/4885CA1 4681/4885CA2 4483/4885 |
| US-20110112308-A1 | Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | HTR3E, HTR3A, HTR3C | CA12 4142/4885CA1 2716/4885CA2 1644/4885 |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ALDH1A2, CRYAB, HSD17B14 | CA12 1060/4885CA1 3267/4885CA2 600/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | CA12 736/4885CA1 1618/4885CA2 285/4885 |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | CYP8B1, CYP26B1, UGT2B7 | CA12 1232/4885CA1 1425/4885CA2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.